Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Platelet-rich plasma significantly improves outcomes in patients with tennis elbow

21.03.2013
Platelet rich plasma (PRP) therapy has been used to manage pain associated with torn tendons, muscles and ligaments, mostly in athletes, at all levels.

Though it has anecdotally been successful, the evidence to support its efficaciousness is weak. Researchers at the Rothman Institute at Jefferson participated in a multi-center randomized prospective study to evaluate the clinical value of PRP versus an active control group to determine its effectiveness in managing the pain and tenderness associated with tennis elbow.

The results will be presented on Thursday, March 21, 2013, at 5 pm, McCormick Place, Room N427 at the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) in Chicago.

Tennis elbow, lateral epicondylar tendinopathy, is characterized by pain radiating from the outside of the elbow to the forearm and back of the hand when grasping or twisting. The pain associated with tennis elbow can be chronic and severe.

Researchers examined 230 patients with chronic tennis elbow. All had at least three months of symptoms and had failed conventional therapy. One hundred sixteen received treatment with PRP and 114 were in the control. All received .25 percent of the anesthetic bupivacaine with epinephrine, then the PRP group received one injection of PRP placed in the extensor tendon. Both groups were followed for up to 24 weeks. No differences were noted between the PRP and control groups prior to treatment.

PRP was prepared from venous whole blood via a desktop centrifuge and disposable canister at the point of care. The centrifuge separated the platelet-rich plasma, concentrated platelets and white blood cells, which were then injected at the site of the patient's injury. In theory, the growth factors that platelets secrete (not including human growth hormone) spur tissue recovery.

At 12 weeks, the PRP patients reported 55 percent improvement in their pain scores compared to 47 percent in the active control group. At 24 weeks, the PRP patients reported 71 percent improvement compared to 56 percent in the control group.

At 12 weeks, 37.4 percent of patients in the PRP group reported significant elbow tenderness versus 48 percent in the control group. At 24 weeks, the numbers again reflected this trend: 29 percent of PRP patients had significant tenderness versus 54 percent in the control. No significant complications occurred in either group.

The study showed the efficacy and level of results that can be obtained when using PRP as part of a treatment regimen. PRP is safe and results in improvements in pain scores and local tenderness compared to an active control group.

Thomas Jefferson University Hospitals

Thomas Jefferson University Hospitals (TJUH) are dedicated to excellence in patient care, patient safety and the quality of the healthcare experience. Consistently ranked by U.S. News & World Report among the nation's top hospitals, Thomas Jefferson University Hospital, established in 1825, has over 900 licensed acute care beds with major programs in a wide range of clinical specialties. TJUH is one of the few hospitals in the U.S. that is both a Level 1 Trauma Center and a federally-designated regional spinal cord injury center. TJUH patient care facilities include Jefferson Hospital for Neuroscience, the region's only dedicated hospital for neuroscience, Methodist Hospital in South Philadelphia, and additional patient care facilities throughout Pennsylvania and New Jersey. TJUH partners with its education affiliate, Thomas Jefferson University.

Lee-Ann Landis | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>